Cancer therapy

Targeting mitochondria and other sub-cellular organelles

Obinna C. Ubah, Heather M. Wallace

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Tumour cell death is required for the clearance of malignant cells and is a vital part of the mechanism of natural tumour suppression. Cancer cells, having acquired multiple deregulated pathways involving several cellular oragenelles, are capable of disrupting these normally finely tuned processes thereby evading both physiological and therapeutic intervention. Although current available data indicate the dependence of successful tumour cell clearance on classical apoptotic pathways (intrinsic and/or extrinsic pathways), there is now evidence suggesting that alternative apoptotic and non-apoptotic pathways may effectively contribute to tumour cell death. The mitochondria, proteasomes, endoplasmic reticulum, Golgi apparatus, lysosomes and lysosome-related organelles of tumour cells exhibit a number of deregulations which have been identified as potential druggable targets for successful rational drug design and therapy. In this review, we summarise the roles of these cellular organelles in tumour initiation and establishment as well as current trends in development of agents that target deregulations in these organelles.

Original languageEnglish
Pages (from-to)201-222
Number of pages22
JournalCurrent Pharmaceutical Design
Volume20
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Organelles
Mitochondria
Neoplasms
Lysosomes
Therapeutics
Cell Death
Drug Design
Golgi Apparatus
Proteasome Endopeptidase Complex
Endoplasmic Reticulum
Drug Therapy

Keywords

  • Apoptosis
  • Cancer therapy
  • Endoplasmic reticulum
  • Golgi apparatus
  • Lysosome
  • MOMP
  • Polyamines
  • Proteasome
  • ROS
  • Warburg effect

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Cancer therapy : Targeting mitochondria and other sub-cellular organelles. / Ubah, Obinna C.; Wallace, Heather M.

In: Current Pharmaceutical Design, Vol. 20, No. 2, 2014, p. 201-222.

Research output: Contribution to journalArticle

@article{658df5b6c598457d941d15976f83c20c,
title = "Cancer therapy: Targeting mitochondria and other sub-cellular organelles",
abstract = "Tumour cell death is required for the clearance of malignant cells and is a vital part of the mechanism of natural tumour suppression. Cancer cells, having acquired multiple deregulated pathways involving several cellular oragenelles, are capable of disrupting these normally finely tuned processes thereby evading both physiological and therapeutic intervention. Although current available data indicate the dependence of successful tumour cell clearance on classical apoptotic pathways (intrinsic and/or extrinsic pathways), there is now evidence suggesting that alternative apoptotic and non-apoptotic pathways may effectively contribute to tumour cell death. The mitochondria, proteasomes, endoplasmic reticulum, Golgi apparatus, lysosomes and lysosome-related organelles of tumour cells exhibit a number of deregulations which have been identified as potential druggable targets for successful rational drug design and therapy. In this review, we summarise the roles of these cellular organelles in tumour initiation and establishment as well as current trends in development of agents that target deregulations in these organelles.",
keywords = "Apoptosis, Cancer therapy, Endoplasmic reticulum, Golgi apparatus, Lysosome, MOMP, Polyamines, Proteasome, ROS, Warburg effect",
author = "Ubah, {Obinna C.} and Wallace, {Heather M.}",
year = "2014",
doi = "10.2174/13816128113199990031",
language = "English",
volume = "20",
pages = "201--222",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Cancer therapy

T2 - Targeting mitochondria and other sub-cellular organelles

AU - Ubah, Obinna C.

AU - Wallace, Heather M.

PY - 2014

Y1 - 2014

N2 - Tumour cell death is required for the clearance of malignant cells and is a vital part of the mechanism of natural tumour suppression. Cancer cells, having acquired multiple deregulated pathways involving several cellular oragenelles, are capable of disrupting these normally finely tuned processes thereby evading both physiological and therapeutic intervention. Although current available data indicate the dependence of successful tumour cell clearance on classical apoptotic pathways (intrinsic and/or extrinsic pathways), there is now evidence suggesting that alternative apoptotic and non-apoptotic pathways may effectively contribute to tumour cell death. The mitochondria, proteasomes, endoplasmic reticulum, Golgi apparatus, lysosomes and lysosome-related organelles of tumour cells exhibit a number of deregulations which have been identified as potential druggable targets for successful rational drug design and therapy. In this review, we summarise the roles of these cellular organelles in tumour initiation and establishment as well as current trends in development of agents that target deregulations in these organelles.

AB - Tumour cell death is required for the clearance of malignant cells and is a vital part of the mechanism of natural tumour suppression. Cancer cells, having acquired multiple deregulated pathways involving several cellular oragenelles, are capable of disrupting these normally finely tuned processes thereby evading both physiological and therapeutic intervention. Although current available data indicate the dependence of successful tumour cell clearance on classical apoptotic pathways (intrinsic and/or extrinsic pathways), there is now evidence suggesting that alternative apoptotic and non-apoptotic pathways may effectively contribute to tumour cell death. The mitochondria, proteasomes, endoplasmic reticulum, Golgi apparatus, lysosomes and lysosome-related organelles of tumour cells exhibit a number of deregulations which have been identified as potential druggable targets for successful rational drug design and therapy. In this review, we summarise the roles of these cellular organelles in tumour initiation and establishment as well as current trends in development of agents that target deregulations in these organelles.

KW - Apoptosis

KW - Cancer therapy

KW - Endoplasmic reticulum

KW - Golgi apparatus

KW - Lysosome

KW - MOMP

KW - Polyamines

KW - Proteasome

KW - ROS

KW - Warburg effect

UR - http://www.scopus.com/inward/record.url?scp=84892963544&partnerID=8YFLogxK

U2 - 10.2174/13816128113199990031

DO - 10.2174/13816128113199990031

M3 - Article

VL - 20

SP - 201

EP - 222

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 2

ER -